{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-158030","form_type":"8-K","ticker":"ATOS","cik":"0001488039","company_name":"ATOSSA THERAPEUTICS, INC.","filed_at":"2026-04-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.353270+00:00","generated_at":"2026-05-15T05:46:26.748486+00:00","sec_items":["8.01"],"event_type":"litigation","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Atossa settles patent disputes with Intas; Endoxifen patents remain enforceable","bullets":["Entered Settlement Agreement on April 13, 2026 with Intas Pharmaceuticals and Jina Pharmaceuticals to resolve Endoxifen patent disputes.","PTAB proceedings will be terminated; U.S. Patent Nos. 11,261,151 and 12,071,391 remain issued and enforceable.","Mutual covenants prevent parties from challenging each other's specified Endoxifen patents and applications.","Agreement preserves Atossa's ability to develop and commercialize Z-endoxifen base in oncology, endocrine disorders, and muscular dystrophy."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-158030","json":"https://secwatch.observer/filing/0001193125-26-158030.json","markdown":"https://secwatch.observer/filing/0001193125-26-158030.md","text":"https://secwatch.observer/filing/0001193125-26-158030.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1488039/000119312526158030/0001193125-26-158030-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1488039/000119312526158030/d107774d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T05:46:26.748486+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}